Qianjiang Yongan Pharmaceutical Co., Ltd.
Symbool: 002365.SZ
SHZ
8.24
CNYMarktprijs vandaag
1753.8874
Koers/Winst Verhouding
28.8139
Koers/Winst Groei Verhouding
2.43B
MRK Kapitalisatie
- 0.01%
DIV Rendement
Qianjiang Yongan Pharmaceutical Co., Ltd. (002365-SZ) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 3696.04 | 956.5 | 832.2 | 547.5 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 2581.9 | 630.4 | 557.5 | 454 | ||||||||||||||||||
balance-sheet.row.net-receivables | 794.98 | 178.4 | 203.1 | 367.8 | ||||||||||||||||||
balance-sheet.row.inventory | 310.95 | 69.9 | 149.6 | 145.8 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 21.25 | 8.8 | 10.4 | 4.8 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 4823.23 | 1213.6 | 1195.3 | 1065.9 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 3948.37 | 970.9 | 1023.5 | 989.3 | ||||||||||||||||||
balance-sheet.row.goodwill | 18.57 | 0.5 | 8.8 | 8.8 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 331.84 | 82.4 | 84.5 | 87.9 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 350.41 | 82.9 | 93.3 | 96.7 | ||||||||||||||||||
balance-sheet.row.long-term-investments | -926.92 | 68.3 | -476.1 | -338.8 | ||||||||||||||||||
balance-sheet.row.tax-assets | 40.83 | 11.3 | 9.7 | 9.9 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 1311.93 | 0.1 | 578.5 | 462.9 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 4724.61 | 1133.5 | 1228.8 | 1220 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 9547.85 | 2347.1 | 2424.2 | 2285.9 | ||||||||||||||||||
balance-sheet.row.account-payables | 542.02 | 128.8 | 162.8 | 114.9 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 93.03 | 47.3 | 40 | 20.4 | ||||||||||||||||||
balance-sheet.row.tax-payables | 56.99 | 7.8 | 4.9 | 5.5 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 0 | ||||||||||||||||||
Deferred Revenue Non Current | 35.42 | 8.5 | 11.3 | 13.1 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 114.65 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | 161.86 | 65.6 | 70.6 | 78.5 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 141.57 | 33.1 | 36 | 35.6 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-liab | 1163.17 | 290.3 | 321.2 | 328.9 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 1178.73 | 294.7 | 294.7 | 294.7 | ||||||||||||||||||
balance-sheet.row.retained-earnings | 3406.61 | 812.7 | 854.5 | 728.2 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 2079.42 | 163.8 | 155.4 | 130.9 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1425.56 | 712.8 | 712.8 | 712.2 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 8090.32 | 1983.9 | 2017.4 | 1865.9 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 9547.85 | 2347.1 | 2424.2 | 2285.9 | ||||||||||||||||||
balance-sheet.row.minority-interest | 285.85 | 64.4 | 85.6 | 91.1 | ||||||||||||||||||
balance-sheet.row.total-equity | 8376.17 | 2048.3 | 2103 | 1957 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 9547.85 | - | - | - | ||||||||||||||||||
Total Investments | 1654.98 | 698.7 | 81.4 | 115.2 | ||||||||||||||||||
balance-sheet.row.total-debt | 93.03 | 47.3 | 40 | 20.4 | ||||||||||||||||||
balance-sheet.row.net-debt | -1021.1 | -278.9 | -234.7 | -73.1 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 1.38 | -12.3 | 132.7 | 119 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.09 | 135.2 | 123.6 | 116 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 6.8 | 2.4 | -3.8 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -176.9 | 0.9 | 12.4 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 106.58 | 93.5 | 99.1 | -152.4 | ||||||||||||||||||
cash-flows.row.account-receivables | 18.85 | 18.9 | 163.2 | -172.1 | ||||||||||||||||||
cash-flows.row.inventory | 87.73 | 87.7 | -10 | -63.7 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | -13.1 | -56.5 | 87.2 | ||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 2.4 | -3.8 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 71.81 | 197.9 | 28.5 | 10.7 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 179.87 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -119.09 | -120.7 | -149.1 | -63 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 0.87 | 1 | 0.4 | -35.9 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | -1350.13 | -1484.2 | -1110.7 | -823.2 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 1299.19 | 1392.7 | 1029 | 943.5 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 22.57 | 45.2 | 0 | 0.5 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -123.95 | -166 | -230.4 | 21.8 | ||||||||||||||||||
cash-flows.row.debt-repayment | -10.6 | -30 | -40 | -132.3 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | -44.62 | -29.5 | -1.6 | -30.7 | ||||||||||||||||||
cash-flows.row.other-financing-activites | -2.27 | -6.3 | 59.4 | 23.8 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -41.19 | -65.8 | 17.8 | -139.2 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 10.45 | 7.1 | 6.5 | -1.1 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 9.69 | 51.5 | 181.2 | -16.7 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 1070.94 | 326.2 | 274.7 | 93.5 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1061.25 | 274.7 | 93.5 | 110.2 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 179.87 | 244.3 | 387.3 | 101.8 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -119.09 | -120.7 | -149.1 | -63 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 60.78 | 123.5 | 238.2 | 38.8 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 852.45 | 962.8 | 1462.4 | 1565.4 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 643.48 | 733.5 | 980.8 | 1206.9 | ||||||||||||||||||
income-statement-row.row.gross-profit | 208.97 | 229.3 | 481.7 | 358.5 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 41.02 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 73.14 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 18.03 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | -94.9 | -1.2 | 66.2 | 69.7 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 280.6 | 205 | 320.3 | 228.6 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 924.08 | 938.5 | 1301.1 | 1435.4 | ||||||||||||||||||
income-statement-row.row.interest-income | 1.56 | 1.9 | 0.3 | 0.2 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0.4 | 0.4 | 0.7 | 2.4 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 18.03 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 66.41 | -20.9 | 0.7 | -1.8 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | -94.9 | -1.2 | 66.2 | 69.7 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | 66.41 | -20.9 | 0.7 | -1.8 | ||||||||||||||||||
income-statement-row.row.interest-expense | 0.4 | 0.4 | 0.7 | 2.4 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 59.89 | 135.2 | 167.1 | 132.3 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | -1.6 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | -43.84 | 24.3 | 152.4 | 131.7 | ||||||||||||||||||
income-statement-row.row.income-before-tax | 22.57 | 3.4 | 153.1 | 129.9 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | 38.46 | 34.5 | 20.3 | 10.8 | ||||||||||||||||||
income-statement-row.row.net-income | 1.38 | -12.3 | 140.3 | 111.4 |
Vaak gestelde vragen
Wat is Qianjiang Yongan Pharmaceutical Co., Ltd. (002365.SZ) totale activa?
Qianjiang Yongan Pharmaceutical Co., Ltd. (002365.SZ) totale activa is 2347138093.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 360799673.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.245.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 0.002.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -0.051.
Wat is Qianjiang Yongan Pharmaceutical Co., Ltd. (002365.SZ) nettowinst (netto-inkomen)?
De nettowinst is -12312563.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 47305897.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 205002116.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 244645727.000.